Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi (amifampridine) following a favourable Canadian Federal Court of Appeal ruling

17 January 2023 - Medunik Canada is pleased to announce that on 9 January 2023, the Federal Court of Appeal of ...

Read more →

Catalyst Pharmaceuticals and KYE Pharmaceuticals announce a second favourable Canadian Federal Court ruling setting aside approval of Ruzurgi

11 March 2022 - Catalyst Pharmaceuticals and KYE Pharmaceuticals today announced receipt of a favourable decision from the Federal Court of ...

Read more →

After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug

3 June 2021 - In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug after ...

Read more →

Health Canada ordered to release confidential drug company data on HPV vaccines

13 July 2018 - Federal government insisted drug companies' clinical trial data is 'confidential business information'. ...

Read more →

Update on biosimilars

27 June 2018 - In the first half of 2018, Health Canada approved three biosimilars based on three different reference ...

Read more →